Compare AstraZeneca plc (AZN) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs GE Vernova Inc — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while GE Vernova Inc trades at $1,042 (market cap $269.50B). The key difference: AstraZeneca plc and GE Vernova Inc are close in size by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | GEV | |
|---|---|---|
Market Cap | $248.14B | $269.50B |
Sector | Health | Technology |
52-Week High | $209.48 | $1.17K |
52-Week Low | $147.06 | $547.96 |
Enterprise Value | $275.41B | $259.17B |
Dividend Yield | 2.01% | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
GE Vernova (GEV) trades at $1,039.90, up 4.95% in the last session, supported by strong technical momentum and bullish analyst sentiment. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains robust revenue growth and a massive $176 billion backlog. Valuation metrics remain elevated with a P/E of 29.01 and EV/EBITDA of 86.33, reflecting high growth expectations tied to AI-driven power demand.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, though premium valuation and execution risks on backlog conversion warrant caution. Strong institutional support with 76% buy ratings and consensus price target of $1,270 suggests upside potential, but investors should monitor quarterly execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
